Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

895
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
895
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

2.9K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapidly progressive dementia with parkinsonism in the Italian CJD Registry: underlying pathology and clinical-biomarker clues for differential diagnosis.

Parkinsonism & related disorders·2026
Same author

Neurodegenerative diseases and environmental risk factors: an overview of the available scientific evidence.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Inclusive Language for Inclusive Care-A Proposal for an LGBTQI<sup>+</sup> Glossary for European Neurologists.

European journal of neurology·2026
Same author

Pain in Functional Motor Disorders: Clinical Correlates From the Italian Registry.

European journal of neurology·2026
Same author

Trazodone for management of depression in Parkinson's disease: expert opinion and proposal for a treatment algorithm.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Real-world insights into coronary CTA prognostication: value of semiquantitative scores.

La Radiologia medica·2026

Related Experiment Video

Updated: Mar 13, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

15.0K

Pregabalin for essential tremor.

Elisa Bruno1, Alessandra Nicoletti, Graziella Quattrocchi

  • 1Department GF Ingrassia,Section of Neurosciences, University of Catania, Catania, Italy, 95123.

The Cochrane Database of Systematic Reviews
|November 2, 2016
PubMed
Summary
This summary is machine-generated.

The efficacy of pregabalin for essential tremor (ET) is uncertain. A single, low-quality study found no significant improvement in motor function or quality of life compared to placebo.

More Related Videos

Generation of Local CA1 &#947; Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

9.6K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.6K

Related Experiment Videos

Last Updated: Mar 13, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

15.0K
Generation of Local CA1 &#947; Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

9.6K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.6K

Area of Science:

  • Neurology
  • Movement Disorders
  • Clinical Pharmacology

Background:

  • Essential tremor (ET) is a common movement disorder with limited treatment options.
  • Current treatments like primidone and propranolol are ineffective for many patients and can cause adverse events.
  • Pregabalin is being investigated as an alternative treatment for ET, but its efficacy and safety remain unclear.

Purpose of the Study:

  • To systematically evaluate the effectiveness and safety of pregabalin compared to placebo or other treatments for essential tremor in adults.

Main Methods:

  • A comprehensive systematic search was conducted across multiple databases up to December 2015.
  • Included were randomized controlled trials (RCTs) meeting specific diagnostic criteria for ET.
  • Data extraction, risk of bias assessment, and statistical analysis (inverse variance, Mantel-Haenszel methods) were performed.

Main Results:

  • Only one small RCT (22 participants) met the inclusion criteria, with a very low quality of evidence.
  • Pregabalin did not show significant improvement in motor tasks or functional abilities compared to placebo on the Fahn-Tolosa-Marin Tremor Rating Scale.
  • No significant differences were observed in study withdrawal rates or adverse events between pregabalin and placebo groups.

Conclusions:

  • The current evidence on pregabalin for essential tremor is very limited and of low quality.
  • A single small study found no benefit, but high risk of bias and lack of further research prevent definitive conclusions.
  • Further high-quality RCTs are needed to determine the true efficacy and safety of pregabalin for ET.